Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival
FDA Approves Afinitor-Aromasin Regimen For Advanced HER2-Negative Breast Cancer
Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints
Upper Endoscopy Most Effective When Performed in 3-Year Intervals
Women Who Concieve Using Fertility Drugs Have a Higher Risk Of Breast Cancer Than Non-Users
Variation in Breast Density May Be Strong Risk Factor
Study: Molecular Breast Imaging Can Be As Effective as MRI
Mammography Had Limited Impact Among Swedish Women Age 40-69
High Vitamin E Consumption Can Lower Liver Cancer Risks
Gene Expression Test Accurately Classifies “Inconclusive” Samples
CAP, ASCCP Recommendations Standardize Lesion Terminology
NCI-Approved CTEP Trials For The Month of July
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ
